Sellas Life Sciences shares have been on a tear, but the ride is getting bumpy. After hitting a new multi-year high of €15.25 during the session, the stock reversed sharply to close at €12.50 — a daily decline of 8.42%. The pullback came just days after the stock posted a 52-week peak of €14.40, representing a 662% annual gain. The whipsaw action highlights the intense speculation surrounding both the company’s lead drug candidate and whispers of a takeover.
At the heart of the volatility sits the Phase 3 REGAL trial for galinpepimut-S (GPS), a therapy for acute myeloid leukemia. As of mid-May, 78 of the 80 survival events required for the primary analysis had been recorded. Once the final two events occur, the data will be unblinded. Market observers take the slow ticking of the last events as a positive sign: patients on the treatment arm may be living longer than the statistical models predicted. Whether that advantage belongs to GPS or the control group remains unknown until the results are published.
Alongside the clinical countdown, the board has been quietly paving the way for a change of control. Management recently amended the severance agreements for CEO Dr. Angelos Stergiou and CFO John Burns, switching to a lump-sum payout structure in the event of a change of control. In the biotech industry, such revisions are often a precursor to a sale, clearing away potential liabilities for an acquirer. The timing has only fueled merger speculation.
Should investors sell immediately? Or is it worth buying Sellas Life Sciences?
Sellas is well financed for whatever comes next. At the end of March, the company held $107.1 million in cash. An additional $28.7 million flowed in during April and May from the exercise of warrants, bringing the pro-forma war chest to roughly $136 million. With that cushion, management has said the company’s operations are funded through 2028, removing the immediate pressure to tap capital markets.
Beyond GPS, Sellas is advancing a second asset, the CDK9 inhibitor SLS009. Phase 2 data are expected in the fourth quarter, offering a potential second commercial pillar. The stock’s technical indicators, however, flash caution. The relative strength index (RSI) stands at 87, deep in overbought territory, and the 127% volatility figure underscores the market’s jittery mood.
The next major catalyst is unambiguous: the final readout of the REGAL study. If the data are positive, the company intends to file for regulatory approval in the second half of 2026. For now, investors are left counting survival events and parsing management moves — a tense wait that is keeping both bulls and bears on edge.
Ad
Sellas Life Sciences Stock: Buy or Sell?! New Sellas Life Sciences Analysis from June 30 delivers the answer:
The latest Sellas Life Sciences figures speak for themselves: Urgent action needed for Sellas Life Sciences investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from June 30.
Sellas Life Sciences: Buy or sell? Read more here...
